Hypereosinophilic Syndrome Treatment Study

I'm Interested!

A Multicentre, Randomised, Doubleblind, Parallel-group, Placebo controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

Sex: Any
Age: Child (Birth - 17), Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase III
Conditions Being Studied: Hypereosinophilic Syndrome

Study Purpose

HES (Hypereosinophilic Syndrome) is a disease characterized by high levels of eosinophils (a particular type of white blood cell) in your blood and a build-up of eosinophils in some organs and tissues (like skin, heart, lungs, intestines or others) causing their dysfunction. Benralizumab is an antibody (i.e. biologic drug) that has been made to reduce the number of eosinophils in the body. A previous benralizumab HES study showed that benralizumab may reduce eosinophils in blood and tissues in patients with severe HES that is not well controlled by standard of care medications. The purpose of this study is to see if benralizumab, given as injections under the skin, can help control your HES better if it is added to available standard of care HES medications which you are currently taking